BWAY:NSD-Brainsway Ltd (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 9.05

Change

0.00 (0.00)%

Market Cap

USD 0.15B

Volume

0.02M

Average Target Price

USD 13.50 (+49.17%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

N/A

USD58.21B 89.66 51.87
IDXX IDEXX Laboratories, Inc

N/A

USD45.81B 79.73 58.69
DXCM DexCom, Inc

N/A

USD38.69B 79.06 100.37
EXAS Exact Sciences Corporation

N/A

USD21.99B N/A N/A
GH Guardant Health, Inc

N/A

USD15.92B N/A N/A
OZON Ozon Holdings PLC

N/A

USD12.78B N/A N/A
ICLR ICON Public Limited Company

N/A

USD10.79B 33.25 22.56
PRAH PRA Health Sciences, Inc

N/A

USD10.44B 53.21 26.30
NTRA Natera, Inc

N/A

USD9.37B N/A N/A
SYNH Syneos Health, Inc

N/A

USD8.99B 47.13 21.81

ETFs Containing BWAY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.03% 62% D- 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.03% 62% D- 68% D+
Trailing 12 Months  
Capital Gain 18.30% 25% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.30% 25% F 24% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.59% 16% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.59% 16% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 19.00% 95% A 77% C+
Risk Adjusted Return -66.27% 7% F 4% F
Market Capitalization 0.15B 24% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.58 46% F 24% F
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -24.56% 58% F 34% F
Return on Invested Capital -23.10% 52% F 27% F
Return on Assets -8.30% 59% F 30% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.60 89% B+ 77% C+
Short Percent N/A N/A N/A N/A N/A
Beta 0.89 62% D- 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.